Skip to main content
PMC home page
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2002 Nov 15;58(1):67–92. doi: 10.1016/0163-7258(93)90067-N

Liver cytoprotection by prostaglandins

Jorge Quiroga 1, Jesus Prieto 1,∗
PMCID: PMC7133752  PMID: 8415874

Abstract

During the last decade intensive work on the relationships between the liver and the arachidonic acid cascade has greatly expanded our knowledge of this area of research. The liver has emerged as the major organ participating in the degradation and elimination of arachidonate products of systemic origin. The synthesis in the liver of arachidonate products derived from the cfyclooxygenase, lipoxygenase and cytochrome P450 system pathways has been demonstrated. The participation of leukotriene B4 and cysteinyl-leukotrienes as mediators of liver damage and the possible therapeutic usefulness of prostaglandins (PGs) in acute liver injury has attracted the interest of clinicians. This article reviews the essential features regarding the role of arachidonate metabolites in liver disease and specially focuses on the cytoprotective effects on the liver displayed by PGE2, PGE1, PGI2 and synthetic PG analogs in experimental models of liver damage induced by ischemia-reperfusion injury, carbon tetrachloride, bacterial lipopolysaccharide and viral hepatitis and on the possible mechanisms underlying liver cytoprotection in these experimental models. The therapeutic usefulness of PGs in clinical practice is critically analyzed on the basis of available evidence in patients with fulminant hepatic failure and primary graft nonfunction following liver transplantation.

Associate Editor: J. Reichen

References

  1. Abecassis M., Falk J.A., Makowka L., Dindzans V.J., Falk R.E., Levy G.A. 16,16 Dimethyl prostaglandin E2 prevents the development of fulminant hepatitis and blocks the induction of monocyte/macrophage procoagulant activity after murine hepatitis virus strain 3 infection. J. clin. Invest. 1987;80:881–889. doi: 10.1172/JCI113147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Aderem A., Cohen D., Wright S., Cohn Z. Bacterial lipopolysaccharides prime macrophages for enhanced release of arachidonic acid metabolites. J. exp. Med. 1986;164:165–179. doi: 10.1084/jem.164.1.165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Alph M.H., Hickman R. The effect of prostaglandins, branched-chain amino acids and other drugs on the outcome of experimental acute porcine hepatic failure. J. Hepat. 1987;4:99–107. doi: 10.1016/s0168-8278(87)80016-8. [DOI] [PubMed] [Google Scholar]
  4. Andreis P.G., Whitfield J.F., Armato U. Stimulation of DNA synthesis and mitosis of hepatocytes in primary cultures of neonatal rat liver by arachidonic acid and prostaglandins. Exp. Cell. Res. 1981;134:265–272. doi: 10.1016/0014-4827(81)90425-0. [DOI] [PubMed] [Google Scholar]
  5. Andreone P., Cursaro C., Ciriaci A.M., Buzzi A., Miniero R., Gasbarrini G. IFN-α increases PGE2 synthesis by cultured liver biopsies in patients with chronic active hepatitis. Gastroenterology. 1992;102:A775. [Google Scholar]
  6. Andreone P., Cursaro C., Miniero R., Sprovieri C., Gasbarrini G. Indomethacin increases serum 2′,5′-oligoadenylate synthetase before and after IFN-α in HBV-positive chronic active hepatitis. J. Hepat. 1992;16(Suppl. 1):S20. doi: 10.1016/s0168-8278(05)80606-3. [DOI] [PubMed] [Google Scholar]
  7. Andus T., Ramadori G., Heinrich P., Knittel T., Meyer zum Büschenfelde K.H. Cultured Ito cells of rat liver express the alpha-2 macroglobulin gene. Eur. J. Biochem. 1987;168:641–646. doi: 10.1111/j.1432-1033.1987.tb13464.x. [DOI] [PubMed] [Google Scholar]
  8. Araki H., Lefer A.M. Cytoprotective actions of prostacyclin during hypoxia in the isolated cat liver. Am. J. Physiol. 1980;238:H176–H180. doi: 10.1152/ajpheart.1980.238.2.H176. [DOI] [PubMed] [Google Scholar]
  9. Ballet F. Role des prostaglandines et des leucotrienes dans l'hépatotoxicité expérimentale. Gastroenterol. clin. Biol. 1989;13:712–719. [PubMed] [Google Scholar]
  10. Bauer J., Birmelin M., Northoff G.H., Northemann W., Tran-Thi T.A., Ueberberg H., Decker K., Heinrich P.C. Induction of rat alpha-2 macroglobulin in vivo and in hepatocyte primary cultures: synergistic action of glucocorticoids and a Kupffer cell-derived factor. FEBS Lett. 1984;177:89–94. doi: 10.1016/0014-5793(84)80987-4. [DOI] [PubMed] [Google Scholar]
  11. Bellomo G., Orrenius S. Altered thiol and calcium homeostasis in oxidative hepatocellular injury. Hepatology. 1985;5:876–882. doi: 10.1002/hep.1840050529. [DOI] [PubMed] [Google Scholar]
  12. Ben-Zvi Z., Weissman-Teitellmann B., Katz S., Danon A. Acetaminophen hepatotoxicity: is there a role for prostaglandin synthesis? Arch. Toxic. 1990;64:299–304. doi: 10.1007/BF01972990. [DOI] [PubMed] [Google Scholar]
  13. Bernuau J., Babany G., Bourliere M., Pauwels A., Metreau J.M., Samuel D., Saliba F., Erlinger S., Benhamou J.P. Prostaglandin E1 (PGE1) has no beneficial effect in patients with either severe or fulminant hepatitis B. Hepatology. 1990;12:875. [Google Scholar]
  14. Bernuau J., Babany G., Pauwels A., Metreau J.M., Bourliere M., Valla D., Samuel D., Saliba F., Erlinger S., Benhamou J.P. Prostaglandin E1 (PGE1) has no beneficial effect in patients with either severe or fulminant hepatitis due to drugs or of undetermined etiology. Hepatology. 1990;12:931. [Google Scholar]
  15. Besse T., Gustin T., Claeys N., Schoeyers P., Lambotte L. Effect of PGI2 and thromboxane antagonist on liver ischemic injury. Eur. Surg. Res. 1989;21:213–217. doi: 10.1159/000129026. [DOI] [PubMed] [Google Scholar]
  16. Bhatnagar R., Schade U., Rietschel T.E., Decker K. Involvement of prostaglandin E and cyclic adenosine 3′5′-monophosphate in lipopolysaccharide-stimulated collagenase release by rat Kupffer cells. Eur. J. Biochem. 1982;125:125–130. doi: 10.1111/j.1432-1033.1982.tb06659.x. [DOI] [PubMed] [Google Scholar]
  17. Birmelin M., Decker K. Synthesis of prostanoids and cyclic nucleotides by phagocytosing rat Kupffer cells. Eur. J. Biochem. 1984;142:219–225. doi: 10.1111/j.1432-1033.1984.tb08274.x. [DOI] [PubMed] [Google Scholar]
  18. Brass E.P., Garrity M.J. Structural specificity for prostaglandin effects on hepatocyte glycogenolysis. Biochem. J. 1990;267:59–62. doi: 10.1042/bj2670059. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Brouwer A., Hendriks H.F.J., Knook D.L. The role of eicosanoids in the acute phase response. J. Hepat. 1990;11:283–286. doi: 10.1016/0168-8278(90)90208-9. [DOI] [PubMed] [Google Scholar]
  20. Brouwer A., Barelds R.J., de Leeuw A.M., Blaw E., Plas A., Yap S.H., Van den Broek A.M., Knook D.L. Isolation and culture of Kupffer cells from human liver. Ultrastructure, endocytosis and prostaglandin synthesis. J. Hepat. 1988;6:36–49. doi: 10.1016/s0168-8278(88)80460-4. [DOI] [PubMed] [Google Scholar]
  21. Buko V.U., Zavodnik I.B. Effect of acetaldehyde on binding of prostaglandins by receptors of liver plasma membranes. Alcohol Alcohol. 1990;25:483–487. [PubMed] [Google Scholar]
  22. Busam K.J., Bauer T.M., Bauer J., Gerok W., Decker K. Interleukin-6 release by rat liver macrophages. J. Hepat. 1990;11:367–373. doi: 10.1016/0168-8278(90)90223-e. [DOI] [PubMed] [Google Scholar]
  23. Caldwell-Kenkel J.C., Currin R.T., Tanaka Y., Thurman R.G., Lemasters J.J. Kupffer cell activation and endothelial cell damage after storage of rat livers: effect of reperfusion. Hepatology. 1991;13:83–95. [PubMed] [Google Scholar]
  24. Callery M.P., Mangino M.J., Flye M.W. Kupffer cell prostaglandin E2 production is amplified during hepatic regeneration. Hepatology. 1991;14:368–372. [PubMed] [Google Scholar]
  25. Camps J., Civeira P., Prieto J. Chronic hepatitis. In: Prieto J., Rodés J., Shafritz D.A., editors. Hepatobiliary Diseases. 1st edn. Springer-Verlag; Berlin: 1992. pp. 281–321. [Google Scholar]
  26. Capdevila J., Marnett L.J., Chacos N., Prough R.A., Estabrook R. Vol. 79. 1982. Cytochrome P450 dependent oxygenation of arachidonic acid to hydroxyeicosatetranoic acids; pp. 767–770. (Proc. natn. Acad. Sci. U.S.A.). [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Capdevila J., Pramanik B., Napoli J.L., Manna S., Falck J.R. Arachidonic acid epoxidation: epoxyeicosatrienoic acids are endogenous constituents of rat liver. Arch. Biochem. Biophys. 1984;231:511–517. doi: 10.1016/0003-9861(84)90415-6. [DOI] [PubMed] [Google Scholar]
  28. Casini A.F., Farber J.L. Dependence of carbon tetrachloride-induced death of cultured hepatocytes on the extracellular calcium concentration. Am. J. Path. 1981;105:138–148. [PMC free article] [PubMed] [Google Scholar]
  29. Chojkier M., Fierer J. D-Galactosamine hepatotoxicity is associated with endotoxin sensitivity and mediated by lymphoreticular cells in mice. Gastroenterology. 1985;88:115–121. doi: 10.1016/s0016-5085(85)80142-6. [DOI] [PubMed] [Google Scholar]
  30. Combis J.M., Semret M., Badia P., Pich D., Pascal J.P., Pipy B., Huet P.M. Eicosanoid and TNFα production by Kupffer cells following hypoxia-reoxygenation. Hepatology. 1991;14:51A. [Google Scholar]
  31. Dave J.R., Knazek R.A. Vol. 77. 1980. Prostaglandin I2 modifies both prolactin binding capacity and fluidity of mouse liver membranes; pp. 6597–6600. (Proc. natn. Acad. Sci. U.S.A.). [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Deakin C.D., Fagan E.A., Williams R. Cytoprotective effects of calcium channel blockers. Mechanisms and potential applications in hepatocellular injury. J. Hepat. 1991;12:251–255. doi: 10.1016/0168-8278(91)90947-a. [DOI] [PubMed] [Google Scholar]
  33. Decker K., Dieter P. the stimulus-activated Na+/H+ exchange in macrophages, neutrophils and platelets. In: Häussinger D., editor. pH Homeostasis: Mechanisms and Control. Academic Press; London: 1987. pp. 79–96. [Google Scholar]
  34. De Knegt R.J., Schalm S.W. Fulminant hepatic failure: to transplant or not to transplant? Neth. J. Med. 1991;38:131–141. [PubMed] [Google Scholar]
  35. Dennis E.A. Regulation of eicosanoid production: role of phospholipases and inhibitors. Biotechnology. 1987;5:1294–1300. [Google Scholar]
  36. Eisenthala A. Indomethacin up-regulates the generation of lymphokine-activated killer cell activity and antibody-dependent cellular cytotoxicity mediated by interleukin-2. Cancer Immun. Immunother. 1990;31:342–348. doi: 10.1007/BF01741405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Fantone J.C., Kunkel S.L., Ward P.A., Zurier R.B. Suppression by prostaglandin E1 of vascular permeability induced by vasoactive inflammatory mediators. J. Immun. 1980;125:2591–2596. [PubMed] [Google Scholar]
  38. Farber J.L. Xenobiotics, drug metabolism and liver injury. In: Farber E., Phillips M.J., Kaufman N., editors. Williams and Wilkins; Baltimore: 1987. pp. 43–53. (Monographs in Pathology, Vol. 28: Pathogenesis of Liver Diseases). [PubMed] [Google Scholar]
  39. Ferrero M.E., Marini A., Rovati M., Aimini R., Salari P.C., Gaja C. Defibrotide, a stimulator of prostacyclin (PGI2) production, prevents the effects of ischemic damage. Int. J. Tissue React. 1989;11:179–184. [PubMed] [Google Scholar]
  40. Fey G.H., Gauldie J. The acute phase response of the lvier in inflammation. In: Popper H., Shafritz D., editors. Vol. IX. W. B. Saunders; Philadelphia: 1990. pp. 89–116. (Progress in Liver Diseases). [PubMed] [Google Scholar]
  41. Fitzpatrick F.A., Murphy R.C. Cytochrome P450 metabolism of arachidonic acid: formation and biological actions of ‘epoxygenase’-derived eicosanoids. Pharmac. Rev. 1988;40:229–241. [PubMed] [Google Scholar]
  42. Flower R.J., Blackwell G.J. Anti-inflammatory steroids induce byosynthesis of a phospholipase inhibitor which prevents prostaglandin generation. Nature (London) 1979;278:456–459. doi: 10.1038/278456a0. [DOI] [PubMed] [Google Scholar]
  43. Ford-Hutchinson A.W. Modification of the lipoxygenase pathway of arachidonic acid metabolism. In: Samuelsson B., Dahlén S.E., Fritsch J., Hedqvist P., editors. Vol. 20. Raven Press, Ltd; New York: 1990. pp. 161–169. (Advances in Prostaglandin, Thromboxane and Leukotriene Research). [PubMed] [Google Scholar]
  44. Funk-Brentano C., Tinal M., Degott C., Leteron P., Babany G., Pessayre D. Protective effect of 16,16-dimethyl prostaglandin E2 on the hepatotoxicity of bromobenzene in mice. Biochem. Pharmac. 1984;33:89–96. doi: 10.1016/0006-2952(84)90374-5. [DOI] [PubMed] [Google Scholar]
  45. Gómez-Foix A.M., Rodríguez-Gil J.E., Guinovart J.J., Bosch F. Prostaglandins E2 and F2æ increase fructose 2,6,-biphosphate levels in isolated hepatocytes. Biochem. J. 1991;274:309–312. doi: 10.1042/bj2740309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Goodwin J.S., Clay G.A. Effect of misoprostol on immune function in elderly subjects. Prostaglandins. 1986;33:61–67. doi: 10.1016/0090-6980(87)90049-9. (Suppl.) [DOI] [PubMed] [Google Scholar]
  47. Goto M., Kawano S., Yoshihara H., Takei Y., Hijioka T., Fukui H., Matsunaga T., Oshita M., Kashiwagi T., Fusamoto H., Kamada T., Sato N. Hepatic tissue oxygenation as a predictive indicator of ischemia-reperfusion liver injury. Hepatology. 1992;15:432–437. doi: 10.1002/hep.1840150313. [DOI] [PubMed] [Google Scholar]
  48. Gove C.D., Hughes R.D., Kmiec Z., Noda Y., Williams R. In vivo and in vitro studies on the protective effects of 9-β-methylcarbacyclin, a stable prostacyclin analog, in galactosamine-induced hepatocellular damage. Prostaglandins Leukotriene Essential Fatty Acids. 1990;49:73–77. doi: 10.1016/0952-3278(90)90120-a. [DOI] [PubMed] [Google Scholar]
  49. Green R.M., Rosenbluth A.B., Whiting J.F., Gollan J.L. the cytokine interleukin-6 inhibits hepatocyte bile salt uptake: implications for the cholestasis of sepsis and inflammatory disease. Gastroenterology. 1992;102:A814. [Google Scholar]
  50. Greig P.D., Woolf G.M., Abecassis M., Forster J., Strasberg S.M., Taylor B.R., Superina R.A., Glynn M.F.X., Ettles M., Blendis L.M., Levy G.A. Vol. 21. 1989. Treatment of primary liver graft non-fuction with prostaglandin E1 results in increased graft and patient survival; pp. 2385–2388. (Transplant Proc.). [PubMed] [Google Scholar]
  51. Guarner F., Fremont-Smith M., Corzo J., Quiroga J., Rodríguez J.L., Prieto J. In vivo and in vitro effects of arachidonic acid products on liver cell integrity following carbon tetrachloride poisoning. In: Samuelsson B., Paoletti R., Ramwell P., editors. Vol. 12. Raven Press; New York: 1983. pp. 75–82. (Advances in Prostaglandin, Thromboxane and Leukotriene Research). [PubMed] [Google Scholar]
  52. Guarner F., Fremont-Smith M., Prieto J. Cytoprotective effect of prostaglandins on isolated rat liver cells. Liver. 1985;5:35–39. doi: 10.1111/j.1600-0676.1985.tb00013.x. [DOI] [PubMed] [Google Scholar]
  53. Guarner F., Boughton-Smith N.K., Blackwell G.J., Moncada S. Reduction by prostacyclin of acetaminophen-induced toxicity in the mouse. Hepatology. 1988;8:249–253. doi: 10.1002/hep.1840080210. [DOI] [PubMed] [Google Scholar]
  54. Hagmann W., Denzlinger C., Keppler D. Role of peptide leukotrienes and their hepatobiliary elimination in endotoxin action. Circ. Shock. 1984;14:223–235. [PubMed] [Google Scholar]
  55. Hagmann W., Steffan A.M., Kirn A., Keppler D. Leukotrienes as mediators in from virus 3-induced hepatitis in rats. Hepatology. 1987;7:732–736. doi: 10.1002/hep.1840070419. [DOI] [PubMed] [Google Scholar]
  56. Hagmann W., Kaiser I., Jakschik B.A. The sensitized liver represents a rich source of endogenous leukotrienes. Hepatology. 1991;13:482–488. [PubMed] [Google Scholar]
  57. Hagmann W., Hacker H.J., Buchholz U. Resident mast cells are the main initiators of anaphylactic leukotriene production in the liver. Hepatology. 1992;16:1477–1484. doi: 10.1002/hep.1840160625. [DOI] [PubMed] [Google Scholar]
  58. Ham E.A., Soderman D.D., Zanatti M.E., Dougherty H.W., McCauley E., Kuehl F.A. Vol. 80. 1983. Inhibition by prostaglandins of leukotriene B4 release from activated neutrophils; pp. 4339–4353. (Proc. natn. Acad. Sci. U.S.A.). [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Hashimoto S., Seyama Y., Yokokura T., Mutai M. Cytotoxic factor production by Kupffer cells elicited with Lactobacillus casei and Corynebacterium parvum. Cancer Immun. Immunother. 1985;20:117–121. doi: 10.1007/BF00205677. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Higgs G.A., Vane J.R. Inhibition of cyclooxygenase and lipoxygenase. Br. Med. Bull. 1983;39:265–270. doi: 10.1093/oxfordjournals.bmb.a071831. [DOI] [PubMed] [Google Scholar]
  61. Hirata F., Schiffman E., Venkatasubramanian K., Salomon D., Axelrod J. Vol. 77. 1980. A phospholipase A2 inhibiting protein in rabbit neutrophils induced by glucocorticoids; pp. 2533–2536. (Proc. natn. Acad. Sci. U.S.A.). [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Hoofnagle J.H. Alpha-interferon therapy of chronic hepatitis B. Current status and recommendations. J. Hepat. 1990;11:S100–S107. doi: 10.1016/0168-8278(90)90173-o. [DOI] [PubMed] [Google Scholar]
  63. Horton A.A., Wood J.M. Prevention of thromboxane B2_induced hepatocyte plasma membrane bleb formation by certain prostaglandins and a proteinase inhibitor. Biochim. biophys. Acta. 1990;1022:319–324. doi: 10.1016/0005-2736(90)90280-2. [DOI] [PubMed] [Google Scholar]
  64. Huber M., Keppler D. Eicosanoids and the liver. In: Popper H., Schaffner F., editors. Vol. IX. W.B. Saunders; Philadelphia: 1990. pp. 117–141. (Progress in Liver Diseases). [Google Scholar]
  65. Huber M., Kästner S., Schölmerich J., Gerok W., Keppler D. Analysis of cysteinyl leukotrienes in human urine: enhanced excretion in patients with liver cirrhosis and hepatorenal syndrome. Eur. J. clin. Invest. 1989;19:53–60. doi: 10.1111/j.1365-2362.1989.tb00195.x. [DOI] [PubMed] [Google Scholar]
  66. Hultcrantz R., Bissell D.M., Roll F.J. Iron mediates production of a neutrophil chemoattractant by rat hepatocytes metabolizing ehtanol. J. Clin. Invest. 1991;87:45–49. doi: 10.1172/JCI114999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Iwai M., Jungermann K. Leukotrienes increase glucose and lactate output and decrease flow in perfused rat liver. Biochem. biophys. Res. Commun. 1988;151:283–290. doi: 10.1016/0006-291x(88)90591-8. [DOI] [PubMed] [Google Scholar]
  68. Kaminski D.L., Deshpande Y.G. Evaluation of the F prostaglandins in canine bile flow. Prostaglandins. 1980;20:373–382. doi: 10.1016/s0090-6980(80)80054-2. [DOI] [PubMed] [Google Scholar]
  69. Karck U., Peters T., Decker K. The release of tumor necrosis factor from endotoxin-stimulated rat Kupffer cells is regulated by prostaglandin E2 and dexamethasone. J. Hepat. 1988;7:352–361. doi: 10.1016/s0168-8278(88)80008-4. [DOI] [PubMed] [Google Scholar]
  70. Kawada N., Mizoguchi Y., Sagakami Y., Kobayashi K., Yamamoto S., Morisawa S. Changes in leukotrienes and prostaglandins in the liver tissue of rats in the experimental massive hepatic cell necrosis model. Prostaglandins Leukotriene Essential Fatty Acids. 1990;40:149–155. doi: 10.1016/0952-3278(90)90158-h. [DOI] [PubMed] [Google Scholar]
  71. Keppler D., Hagmann W., Rapp S., Denzlinger C., Koch H.K. The relation of leukotrienes to liver injury. Hepatology. 1985;5:883–891. doi: 10.1002/hep.1840050530. [DOI] [PubMed] [Google Scholar]
  72. Keppler D., Huber M., Baumert T. Leukotrienes as mediators in deseases of rat liver. Semin. Liver Dis. 1981;8:357–366. doi: 10.1055/s-2008-1040557. [DOI] [PubMed] [Google Scholar]
  73. Knazek R.A., Liu S.C., Dave J.R., Christy R.J., Keller J.A. Indomethacin causes a simultaneous decrease of both prolactin binding and fluidity of mouse liver membranes. Prostaglandins Med. 1981;6:403–411. doi: 10.1016/0161-4630(81)90072-0. [DOI] [PubMed] [Google Scholar]
  74. Koo A., Komatsu H., Tao G., Inoue M., Guth P.H., Kaplowitz N. Contribution of no-reflow phenomenon to hepatic injury after ischemia-reperfusion: evidence for a role for superoxide anion. Hepatology. 1991;15:507–514. doi: 10.1002/hep.1840150325. [DOI] [PubMed] [Google Scholar]
  75. Kuiper J., Zijlstra F.J., Kamps J.A., Wan Berkel T.J. Identification of prostaglandin D2 as the major eicosanoid from liver endothelial and Kupffer cells. Biochim. biophys. Acta. 1988;959:143–152. doi: 10.1016/0005-2760(88)90025-2. [DOI] [PubMed] [Google Scholar]
  76. Kunkel S.L., Spengler M., May M.A., Spengler R., Larrick J., Remick D. Prostaglandin E2 regulates macrophage-derived tumor necrosis factor gene expression. J. biol. Chem. 1988;263:5380–5384. [PubMed] [Google Scholar]
  77. Kwon A.H., Uetsuji S., Yamamura M., Hioki K., Yamamoto M. Effect of administration of fibronectin or aprotinin on liver regeneration after experimental hepatectomy. Ann. Surg. 1990;211:295–300. [PMC free article] [PubMed] [Google Scholar]
  78. Lamb R.G., Schwertz D.W. The effects of bromobenzene and carbontetrachloride exposure in vitro on the phospholipase C activity of rat liver cells. Toxic. appl. Pharmac. 1982;63:216–229. doi: 10.1016/0041-008x(82)90044-8. [DOI] [PubMed] [Google Scholar]
  79. Lancaster C., Robert A. Intestinal lesions produced by prednisolone: prevention (cytoprotection) by 16,16 dimethyl prostaglandin E2. Am. J. Physiol. 1978;235:E703–E708. doi: 10.1152/ajpendo.1978.235.6.E703. [DOI] [PubMed] [Google Scholar]
  80. Lapetina E.G., Billah M.M., Cuatrecasas P. The phosphatidylinositol cycle and the regulation of arachidonic acid production. Nature. 1981;292:103–108. doi: 10.1038/292367a0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Lauterburg B.H. Early disturbances of calcium translocation across the plasma membrane in toxic liver injury. Hepatology. 1987;7:1179–1183. doi: 10.1002/hep.1840070602. [DOI] [PubMed] [Google Scholar]
  82. Le Bail B., Balabaud C., Bioulac-Sage P. Anatomy and structure of the liver and biliary tree. In: Prieto J., Rodés J., Shafritz D.A., editors. Hepatobiliary Diseases. Springer-Verlag; Berlin: 1992. pp. 1–38. [Google Scholar]
  83. Lewis R.A. Interactions of eicosanoids and cytokines in immune regulation. In: Samuelsson B., Dahlén S.E., Fritsch J., Hedqvist P., editors. Vol. 20. Raven Press, Ltd; New York: 1990. pp. 170–178. (Advances in Prostaglandin, Thromboxane and Leukotriene Research). [PubMed] [Google Scholar]
  84. Lysz T.W., Billiar T.R., Curran R.D., Simmons R.L., Machiedo G.W. Kupffer cell-hepatocyte interactions and the changes in 1-14C-arachidonate incorporation in response to endotoxin in vitro. Prostaglandins. 1990;39:497–514. doi: 10.1016/0090-6980(90)90033-r. [DOI] [PubMed] [Google Scholar]
  85. MacManus J.P., Braceland B.M. A connection between the production of prostaglandins during liver regeneration and the DNA synthetic response. Prostaglandins. 1976;11:609–620. doi: 10.1016/0090-6980(76)90064-2. [DOI] [PubMed] [Google Scholar]
  86. Mahl T.C., Tzung S.P., Lance P., Andersen V., Cohen S.A. Prostaglandin E2 inhibits tumor necrosis factor production by Kupffer cells and prevents endotoxin induced mortality in mice. Gastroenterology. 1992;102:A846. doi: 10.1002/eji.1830221211. [DOI] [PubMed] [Google Scholar]
  87. Masaki N., Ohta Y., Shirataki H., Ogata I., Hayashi S., Yamada S., Hirata K., Nagoshi S., Mochida S., Tomiya T., Ohno A., Ohno Y., Fujiwara K. Hepatocyte membrane stabilization by prostaglandins E1 and E2: favorable effects on rat liver injury. Gastroenterology. 1992;102:572–576. doi: 10.1016/0016-5085(92)90105-8. [DOI] [PubMed] [Google Scholar]
  88. McCord J.M. Oxygen-derived free radicals in postischemic tissue. New Engl. J. Med. 1985;312:159–163. doi: 10.1056/NEJM198501173120305. [DOI] [PubMed] [Google Scholar]
  89. McNeil G.E., Chen T.S., Leevy L.M. Reversal of ethanol and indomethacin-induced suppression of hepatic DNA synthesis by 16,16 dimethyl prostaglandin E2. Hepatology. 1985;5:43–46. doi: 10.1002/hep.1840050110. [DOI] [PubMed] [Google Scholar]
  90. Medina J.F., Haeggström J., Kumlin M., Mark O. Leukotriene A4: metabolism in different rat tissues. Biochim. biophys. Acta. 1988;961:203–212. doi: 10.1016/0005-2760(88)90115-4. [DOI] [PubMed] [Google Scholar]
  91. Mibas A.A., Subramony C., Markov A.K. Prostaglandin E2 (misoprostol) attenuates the carbon tetrachloride-induced damage in the rat. Gastroenterology. 1991;100:A774. [Google Scholar]
  92. Mieli-Vergani G., Civeira P., Vergani D. Immunology and the liver. In: Prieto J., Rodés J., Shafritz D.A., editors. Hepatobiliary Diseases. Springer-Verlag; Berlin: 1992. pp. 95–116. [Google Scholar]
  93. Miura Y., Fukui N. Prostaglandins as possible triggers for liver regeneration after partial hepatectomy. Cell. molec. Biol. 1979;25:179–184. [PubMed] [Google Scholar]
  94. Miyazaki M., Makowka L., Falk R.E., Falk J.A., McDonnell M., Venturi D. Protection of thermochemotherapeutic-induced lethal acute hepatic necrosis n the rat by 16,16 dimethyl prostaglandin E2. J. Surg. Res. 1983;34:415–426. doi: 10.1016/0022-4804(83)90090-2. [DOI] [PubMed] [Google Scholar]
  95. Mizoguchi Y., Tsutsui H., Miyajima K., Sakagami Y., Seki S., Kobayashi K., Yamamoto S., Morisawa S. The protective effects of prostaglandins E1 in an experimental massive hepatic cell necrosis model. Hepatology. 1987;7:1184–1187. doi: 10.1002/hep.1840070603. [DOI] [PubMed] [Google Scholar]
  96. Mora N.P., Cienfuegos J.A., Bernaldo de Quirss L., Tendillo F., Pereira F., Fores R., Alvarez I., Navidad R., Castillo-Olivares J.L. Vol. 19. 1987. Successful liver allograft function after 24 hr preservation: cumulative effects of prostacyclin plus verapamil; pp. 3932–3936. (Transplant. Proc.). [PubMed] [Google Scholar]
  97. Moran M., Mozes M.F., Maddux M.S., Veremis S., Bartkus C., Ketel B., Pollak R., Wallemark C., Jonasson O. Prevention of acute graft rejection by the prostaglandin E1 analog misoprostol in renal-transplant recipients treated with cyclosporine and prednisone. New Engl. J. Med. 1990;322:1183–1188. doi: 10.1056/NEJM199004263221703. [DOI] [PubMed] [Google Scholar]
  98. Mourelle M., Amezcua J.L., Perez-Alvarez V. Reduction of apparent indicators of liver cirrhosis in rats by the arachidonate lipoxygenase inhibitor BW755c. Eur. J. Pharmacol. 1987;134:175–180. doi: 10.1016/0014-2999(87)90163-4. [DOI] [PubMed] [Google Scholar]
  99. Munthe-Kaas A., Berg T., Seglen P., Seljelid R. Mass isolation and culture of rat Kupffer cells. J. exp. Med. 1975;141:1–10. doi: 10.1084/jem.141.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  100. Nagal H., Aoki M., Shimazawa T., Koda A., Kasahara M. Effect of OKY-046 and ONO-3708 on liver injury in mice. Jap. J. Pharmac. 1988;51:191–197. doi: 10.1254/jjp.51.191. [DOI] [PubMed] [Google Scholar]
  101. Nagal H., Aoki M., Shimazawa T., Yakuo I., Koda A., Kasahara M. The role od thromboxane A2 (TxA2) in liver injury in mice. Prostaglandins. 1989;38:439–446. doi: 10.1016/0090-6980(89)90126-3. [DOI] [PubMed] [Google Scholar]
  102. Nanji A.A., Khettry U., Sadrzadeh S.H.H., Miller-Cassman R., Yamanaka T. Severity of liver injury in experimental alcoholic liver disease: correlation with plasma endotoxin, prostaglandin E2, leukotriene B4 and thromboxane B2. Gastroenterology. 1922;102:A859. [PMC free article] [PubMed] [Google Scholar]
  103. Nanji A.A., Miller-Cassman R., Khettry U., Sadrzadeh S.H.H., Thomas P., Yamanaka T. Relationship between development of experimental alcoholic liver injury and plasma levels of endotoxin and eicosanoids and Kupffer cells supernatant levels of interleukin 1, tumor necrosis factor and eicosanoids. Gastroenterology. 1992;102:A859. [Google Scholar]
  104. Naqpal R., Nunes F.A., Kupperman D., Joyce M., Zigmond S., Brass C.A. Production of a chemokinetic factor during hypoxia and reoxygenation in isolated perfused rat liver. Gastroenterology. 1992;102:A858. [Google Scholar]
  105. Needleman P., Turk J., Jakschik B.A., Morrison A.R., Lefkowitch J.B. Arachidonic acid metabolism. Ann. Rev. Biochem. 1986;55:69–102. doi: 10.1146/annurev.bi.55.070186.000441. [DOI] [PubMed] [Google Scholar]
  106. Noack K.B., Bronk S.F., Kato A., Gores G.J. Bile duct cells are more vulnerable to reoxygenation injury than to anoxia: implications for the pathogenesis of biliary strictures following liver transplantation. Gastroenterology. 1992;102:A861. doi: 10.1097/00007890-199309000-00001. [DOI] [PubMed] [Google Scholar]
  107. O'Brien C.B., Henzel B.S., Naji A., Brass C.A. Prostaglandin E1 infusion is effective in the late treatment of patients with acetaminophen induced acute hepatic failure reffered for liver transplantation. Gastroenterology. 1992;102:A862. [Google Scholar]
  108. O'Brien C.B., Henzel B.S., Naji A., Long W.B. Prostaglandin E1 infusion improve survival of patients with fulminant hepatic failure. Gastroenterology. 1992;102:A862. [Google Scholar]
  109. Ohyashiki T., Ohtsuka T., Mohri T. A change in the lipid fluidity of the porcine intestinal brush-border membranes by lipid peroxidation. Studies using pyrene and fluorescent stearic acid derivatives. Biochim. biophys. Acta. 1986;861:311–318. doi: 10.1016/0005-2736(86)90433-5. [DOI] [PubMed] [Google Scholar]
  110. Okumura T., Saito K. Effect of prostaglandins on glycogenesis and glycogenolysis in primary cultures of rat hepatocytes. A role of prostaglandins D2 n the liver. Prostaglandins. 1990;39:525–540. doi: 10.1016/0090-6980(90)90035-t. [DOI] [PubMed] [Google Scholar]
  111. Olthoff K.M., Wasef E., Seu P., Imagawa D.K., Freischlag J.A., Hart J., Bussutil R.W. PGE1 reduces injury in hepatic allografts following preservation. J. Surg. Res. 1991;50:595–601. doi: 10.1016/0022-4804(91)90048-q. [DOI] [PubMed] [Google Scholar]
  112. Pastan I.H., Johnson G.S., Anderson W.B. Role od cyclic nucleotides in growth control. Ann. Rev. Biochem. 1975;44:491–522. doi: 10.1146/annurev.bi.44.070175.002423. [DOI] [PubMed] [Google Scholar]
  113. Peters M. Vol. 9. 1989. Mechanisms of action of interferons; pp. 235–239. (Semin. Liver Dis). [DOI] [PubMed] [Google Scholar]
  114. Piper P.J. Formation and actions of leukotrienes. Physiol. Rev. 1984;64:744–761. doi: 10.1152/physrev.1984.64.2.744. [DOI] [PubMed] [Google Scholar]
  115. Prescott L.F., Illingworth R.N., Critchley J.A.J.H., Stewart M.J., Adam R.D., Proudfoot A.T. Intravenous N-acetylcysteine: the treatment of choice for paracetamol poisoning. Br. Med. J. 1979;2:1097–1100. doi: 10.1136/bmj.2.6198.1097. [DOI] [PMC free article] [PubMed] [Google Scholar]
  116. Quiroga J. Bile salts, bile flow and cholestasis. In: Prieto J., Rodés J., Shafritz D.A., editors. Hepatobiliary Diseases. Springer-Verlag; Berlin: 1992. pp. 201–280. [Google Scholar]
  117. Quiroga J., Colina I., Demetris A.J., Starzi T., Van Thiel D.H. Cause and timing of first graft failure in liver transplantation. A study of 177 consecutive patients. Hepatology. 1991;14:1054–1062. [PubMed] [Google Scholar]
  118. Quiroga J., Rodríguez-Sanromán J.L., Guarner F., Rodríguez-Ortigosa C., Aréjola J.M., Prieto J. Inhibitors of the lipoxygenase arachidonic acid pathway impair glycocholate efflux in isolated rat hepatocytes. J. Hepat. 1991;12:302–311. doi: 10.1016/0168-8278(91)90831-u. [DOI] [PubMed] [Google Scholar]
  119. Rappaport R.S., Dodge G.R. Prostaglandin E1 inhibits the production of human interleukin 2. J. exp. Med. 1982;155:943–948. doi: 10.1084/jem.155.3.943. [DOI] [PMC free article] [PubMed] [Google Scholar]
  120. Rieder H., Ramadori G., Meyer zum Büschenfelde K.H. Guinea pig Kupffer cells can be activated in vitro to an enhanced superoxide response. I. Comparison with peritoneal macrophages. J. Hepat. 1988;7:338–344. doi: 10.1016/s0168-8278(88)80006-0. [DOI] [PubMed] [Google Scholar]
  121. Rieder H., Ramadori G., Meyer zum Büschenfelde K.H. Guinea pig Kupffer cells can be activated in vitro to an enhanced superoxide response. II. Involvement of eicosanoids. J. Hepat. 1988;7:345–351. doi: 10.1016/s0168-8278(88)80007-2. [DOI] [PubMed] [Google Scholar]
  122. Rieder H., Ramadori G., Allmann K.H., Meyer zum Büschenfelde K.H. Prostanoid release of cultured liver sinusoidal endothelial cells in response to endotoxin and tumor necrosis factor. Comparison with umbilical vein endothelial cells. J. Hepat. 1990;11:359–366. doi: 10.1016/0168-8278(90)90222-d. [DOI] [PubMed] [Google Scholar]
  123. Robert A., Nezamis J.E., Lancaster C., Hanchar A.J. Cytoprotection by prostaglandins in rats. Prevention of gastric necrosis produced by alcohol, HCl, NaOH, hypertonic NaCl and thermal injury. Gastroenterology. 1979;77:433–443. [PubMed] [Google Scholar]
  124. Rodríguez-Ortigosa C.M., Vesperinas I., Quiroga J., Qian C., Medina J.F., Prieto J. Self modulation of bile salt excretion through bile-salt induced enhancement of 5-lipoxygenase expression and peptido leukotriene production in rat liver. J. Hepat. 1992;16(Suppl. 1):S68. [Google Scholar]
  125. Rush B.D., Merrit M.V., Kaluzny M., Schoick T.V., Brunden M.N., Ruwart M. Studies on the mechanism of the protective action of 16,16 dimethyl prostaglandin E2 in carbon tetrachloride-induced acute hepatic injury in the rat. Prostaglandins. 1986;32:439–455. doi: 10.1016/0090-6980(86)90011-0. [DOI] [PubMed] [Google Scholar]
  126. Rush B.D., Wilkinson K.F., Nichols N.M., Ochoa R., Brunden M.N., Ruwart M.J. Hepatic protection by 16,16 dimethyl prostaglandin E2 (DMPG) against acute afflatoxin B1-induced injury in the rat. Prostaglandins. 1989;37:683–693. doi: 10.1016/0090-6980(89)90105-6. [DOI] [PubMed] [Google Scholar]
  127. Ruwart M.J., Rush B.D., Friedle N.M., Piper R.C., Kolaja G.J. Protective effects of 16,16-dimethyl prostaglandin E2 on the liver abd kidney. Prostaglandins. 1981;21:97–102. doi: 10.1016/0090-6980(81)90124-6. (Suppl.) [DOI] [PubMed] [Google Scholar]
  128. Ruwart M.J., Rush B.D., Friedle N.M., Stachura J., Tarnawaski A. 16,16-Dimethyl-PGE2 protection against α-napthylisothiocyanate-induced experimental cholangitis in the rat. Hepatology. 1984;4:658–660. doi: 10.1002/hep.1840040415. [DOI] [PubMed] [Google Scholar]
  129. Ruwart M.J., Rush B.D., Snyder K.F., Peters K.M., Appelman H.D., Henley K.S. 16,16-Dimethyl prostaglandin E2 delays collagen formation in nutritional injury in the rat. Hepatology. 1988;8:61–64. doi: 10.1002/hep.1840080112. [DOI] [PubMed] [Google Scholar]
  130. Sakagami Y., Mizoguchi Y., Seki S., Kobayashi K., Morisawa S., Yamamoto S. Release of peptide leukotrienes from rat Kupffer cells. Biochem. biophys. Res. Commun. 1988;156:217–221. doi: 10.1016/s0006-291x(88)80827-1. [DOI] [PubMed] [Google Scholar]
  131. Samuelson B., Goldyne M., Granström E., Hamberg M., Hammarström S., Malmstein C. Prostaglandins and thromboxanes. Ann. Rev. Biochem. 1978;47:997–1029. doi: 10.1146/annurev.bi.47.070178.005025. [DOI] [PubMed] [Google Scholar]
  132. Schachter D. Fluidity and function of hepatocyte plasma membranes. Hepatology. 1984;4:140–151. doi: 10.1002/hep.1840040124. [DOI] [PubMed] [Google Scholar]
  133. Schalm S.W., De Knegt R.J., Metselaar H.J., Van der Berg B. Acute hepatic failure. In: Prieto J., Rodés J., Shafritz D.A., editors. Hepatobility Diseases. 1st edn. Springer-Verlag; Berlin: 1992. pp. 999–1018. [Google Scholar]
  134. Schanne F.A.X., Kane A.B., Young E.E., Farber J.L. Calcium dependence of toxic cell death: a final common pathway. Science. 1979;206:700–702. doi: 10.1126/science.386513. [DOI] [PubMed] [Google Scholar]
  135. Schnellmann R.G. Mechanisms of tert-butyl hydroperoxyde-induced toxicity to rabbit renal proximal tubules. Am. J. Physiol. 1988;255:28–33. doi: 10.1152/ajpcell.1988.255.1.C28. [DOI] [PubMed] [Google Scholar]
  136. Seelos R., Otto G., Manner M. Vol. 23. 1991. Prostaglandin synthesis and survival after orthotopic liver transplantation in pigs; p. 2420. (Transplant. Proc.). [PubMed] [Google Scholar]
  137. Serhan C.N., Fridovich J., Goetzi E.J., Dunham P.B., Weissmann G. Leukotriene B4 and phosphatidic acid are calcium ionospheres. Studies employing arsenazo III in liposomes. J. biol. Chem. 1982;257:4746–4752. [PubMed] [Google Scholar]
  138. Sheener P., Sinclair S., Greig P., Logan A., Blendis L.M., Levy G. A randomized control trial of prostaglandin E2 (PGE2) in the treatment of fulminant hepatic failure. Hepatology. 1992;16:88A. [Google Scholar]
  139. Shirahama M., Ishibashi H., Tsuchiya Y., Kurokawa S., Okumura Y., Niho Y. Kupffer cells may autoregulate interleukin-1 production by producing interleukin-1 inhibitor and prostaglandin E2. Scand. J. Immunol. 1988;28:719–725. doi: 10.1111/j.1365-3083.1988.tb01505.x. [DOI] [PubMed] [Google Scholar]
  140. Shiratori Y., Tanaka M., Umihara J., Kawase T., Shiina S., Sugomoto T. Leukotriene inhibitors modulate hepatic injury induced by lipopoysaccharide-activated macrophages. J. Hepat. 1990;10:51–61. doi: 10.1016/0168-8278(90)90073-z. [DOI] [PubMed] [Google Scholar]
  141. Sikujara O., Moden M., Toyoshima K., Okamura J., Kosaki G. Cytoprotective effect of prostaglandin I2 on ischemia-induced hepatic cell injury. Transplantation. 1983;36:238–243. doi: 10.1097/00007890-198309000-00002. [DOI] [PubMed] [Google Scholar]
  142. Sinclair S.B., Greig P.D., Blendis L.M., Abecassis M., Roberts E.A., Phillips M.J., Cameron R., Levy G. Biochemical and clinical response of fulminant viral hepatitis to administration of prostaglandin E. A preliminary report. J. clin. Invest. 1989;84:1063–1069. doi: 10.1172/JCI114268. [DOI] [PMC free article] [PubMed] [Google Scholar]
  143. Skouteris G.G., Ord M.G., Stocken L. Regulation of the proliferation of primary rat hepatocytes by eicosanoids. J. Cell Physiol. 1988;135:516–520. doi: 10.1002/jcp.1041350321. [DOI] [PubMed] [Google Scholar]
  144. Stachura J., Tarnawski A., Ivey K.J., Ruwart M.J., Rush B.D., Friedle N.M., Szczudrawa J., Mach T. Cytoprotective effect of 16,16-dimethyl-PGE2 and some drugs on an acute galactosamine induced liver damage in rats. Folia Histochem. Cytochem. 1980;18:311–318. [PubMed] [Google Scholar]
  145. Stachura J., Tarnawski A., Ivey K.J., Mach T., Bogdal J., Szczudrawa J., Klimczyk B. Prostaglandin protection of carbon tetrachloride-induced liver cell necrosis in the rat. Gastroenterology. 1981;81:211–217. [PubMed] [Google Scholar]
  146. Stachura J., Tarnawski A., Ivey K.J., Ruwart M.J., Rush B.D., Friedle N.M., Szczudrawa J., Mach T. 16,16-Dimethyl prostaglandin E2 protection on rat liver against acute injury by galactosamine, acetaminophen, ethanol and ANIT. Gastroenterology. 1981;80:1349. [Google Scholar]
  147. Sutto F., Brault A., Lepage R., Huet P.M. Evaluation of liver endothelial cell (LEC) function using hyaluronic acid (HA) elimination during short cold ischemia. Hepatology. 1991;14:51A. [Google Scholar]
  148. Takei Y., Marzi I., Gao W., Gores G.J., Lemasters J.J., Thurmann R.G. Leukocyte adhesion and cell death following orthotopic liver transplantation in the rat. Transplantation. 1991;51:959–965. doi: 10.1097/00007890-199105000-00005. [DOI] [PubMed] [Google Scholar]
  149. Tate G.A., Mandell B.F., Schumacher H.R., Zurier R.B. Suppression of acute inflammation by 15-methyl prostaglandin E1. Lab. Invest. 1988;59:192–199. [PubMed] [Google Scholar]
  150. Thiele D.L. Revolutionary lifesaving therapy for acute hepatic failure, or yet another false hope? Gastroenterology. 1990;98:1088–1089. doi: 10.1016/0016-5085(90)90039-4. [DOI] [PubMed] [Google Scholar]
  151. Thomas H.J. Management of chronic hepatitis B virus infection. In: Rodés J., Arroyo V., editors. Therapy in Liver Diseases. Ediciones Doyma S.A; Barcelona: 1992. pp. 242–247. [Google Scholar]
  152. Tiegs G., Wendel A. Leukotriene-mediated liver injury. Biochem. Pharmac. 1988;37:2569–2573. doi: 10.1016/0006-2952(88)90248-1. [DOI] [PubMed] [Google Scholar]
  153. Tran-Thi T.A., Gyufko K., Henninger H., Busse R., Decker K. Studies on synthesis and degradation of eicosanoids by rat hepatocytes in primary culture. J. Hepat. 1987;5:322–331. doi: 10.1016/s0168-8278(87)80038-7. [DOI] [PubMed] [Google Scholar]
  154. Tribble D.L., Aw T.Y., Jones D.P. The pathophysiological significance of lipid peroxidation in oxidative cell injury. Hepatology. 1987;7:377–387. doi: 10.1002/hep.1840070227. [DOI] [PubMed] [Google Scholar]
  155. Trudell J.R., Bendix M., Bosterling B. Hypoxia potentiates killing of hepatocytes monolayers by leukotrienes, hydroperoxyeicosatetraenoic acids, or calcium ionophore A23187. Biochim. biophys. Acta. 1984;803:338–341. doi: 10.1016/0167-4889(84)90126-5. [DOI] [PubMed] [Google Scholar]
  156. Tsutsui H., Mizoguchi Y., Yamamoto S. Studies on experimentally-induced acute hepatic failure: possible involvement of activated liver adherent cells. In: Kirn A., Knook D.L., Wisse E., editors. Vol. I. the Kupffer Cell Foundation; Amsterdam: 1986. pp. 307–314. (Cells of the Hepatic Sinusoid). [Google Scholar]
  157. Urakawa T., Azumi Y., Nagahata Y., Matsui S., Nakamoto M., Takeda K., Itoh A., Ichihara T., Moritomo H., Kuroda H., Saitoh Y. Study of 16,16 dimethyl prostaglandin E2 for prevention of stress ulcer after hepatectomy of experimental cirrhotic liver and its influence on hepatic regeneration. Scand. J. Gastroenterol. 1990;25:647–655. doi: 10.3109/00365529008997588. [DOI] [PubMed] [Google Scholar]
  158. Verna R. Effect of prostaglandins on the rat liver plasma membrane-bound Na+/K+ ATPase. In: Braquet P., Garay R.P., Frölich J.C., Nicosia S., editors. Prostaglandins and Membrane Ion Transport. Raven Press; New York: 1984. pp. 233–277. [Google Scholar]
  159. Wendel A., Tiegs G., Werner C. Evidence for the involvement of a reperfusion injury in galactosamine/endotoxin induced hepatitis in mice. Biochem. Pharmac. 1987;36:2637–2639. doi: 10.1016/0006-2952(87)90544-2. [DOI] [PubMed] [Google Scholar]

Articles from Pharmacology & Therapeutics are provided here courtesy of Elsevier

RESOURCES